Osiris Therapeutics Announces Second Quarter 2013 Financial Results
COLUMBIA, Md. -- July 15, 2013
Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will report
its financial results for the second quarter ended June 30, 2013, on Monday,
August 5, 2013. C. Randal Mills, Ph.D., President and Chief Executive Officer,
and Philip R. Jacoby, Jr., Chief Financial Officer, will provide a company
update and discuss results via a webcast and conference call on Monday, August
5, 2013 at 9:00 a.m. ET.
To access the webcast, visit the Investor Relations section of the company's
website at http://investor.osiris.com/events.cfm. Alternatively, callers may
participate in the conference call by dialing (877) 303-6133 (U.S.
participants) or (970) 315-0493 (international participants).
An archive of the webcast will be available approximately two hours after the
completion of the call. To access the archived webcast, visit the Investor
Relations section of the company's website at
About Osiris Therapeutics
Osiris Therapeutics, Inc., is the leading stem cell company, having developed
the world’s first approved stem cell drug, Prochymal®. Osiris currently
markets Grafix® and Ovation® for wound and tissue repair, and Cartiform® for
cartilage repair. Osiris is a fully integrated company with capabilities in
research, development, manufacturing and distribution of cell therapy
products. Osiris has developed an extensive intellectual property portfolio to
protect the company's technology, including 50 U.S. and 156 foreign patents.
Osiris, Prochymal, Chondrogen, Grafix, Ovation and Cartiform are registered
trademarks of Osiris Therapeutics, Inc. More information can be found on the
company's website, www.Osiris.com. (OSIR-G)
This press release contains forward-looking statements. Forward-looking
statements include statements about our expectations, beliefs, plans,
objectives, intentions, assumptions and other statements that are not
historical facts. Words or phrases such as "anticipate," "believe,"
"continue," "ongoing," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project" or similar words or phrases, or the
negatives of those words or phrases, may identify forward-looking statements,
but the absence of these words does not necessarily mean that a statement is
not forward-looking. Examples of forward-looking statements may include,
without limitation, statements regarding any of the following: our product
development efforts; our clinical trials and anticipated regulatory
requirements, and our ability to successfully navigate these requirements; the
success of our product candidates in development; status of the regulatory
process for our biologic drug candidates; implementation of our corporate
strategy; our financial performance; our product research and development
activities and projected expenditures, including our anticipated timeline and
clinical strategy for mesenchymal stem cells and biologic drug candidates and
marketed Biosurgery products (including Prochymal, Chondrogen®, Grafix,
Ovation and Cartiform); our cash needs; patents, trademarks and other
proprietary rights; the safety and ability of our products and potential
products to treat disease; our ability to supply a sufficient amount of our
marketed products or product candidates and, if approved or otherwise
commercially available, products to meet demand; our costs to comply with
governmental regulations; our plans for sales and marketing; our plans
regarding facilities; types of regulatory frameworks we expect will be
applicable to our products and potential products; and results of our
scientific research. Forward-looking statements are subject to known and
unknown risks and uncertainties and are based on potentially inaccurate
assumptions that could cause actual results to differ materially from those
expected or implied by the forward-looking statements. Our actual results
could differ materially from those anticipated in forward-looking statements
for many reasons, including the factors described in the section entitled
"Risk Factors" in our Annual Report on Form 10-K and other Periodic Reports
filed on Form 10-Q, with the United States Securities and Exchange Commission.
Accordingly, you should not unduly rely on these forward-looking statements.
We undertake no obligation to publicly revise any forward-looking statement to
reflect circumstances or events after the date of this press release or to
reflect the occurrence of unanticipated events.
Osiris Therapeutics, Inc.
Aziz Ahmad, 443-545-1834
Press spacebar to pause and continue. Press esc to stop.